1. Home
  2. SYBX vs PT Comparison

SYBX vs PT Comparison

Compare SYBX & PT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYBX
  • PT
  • Stock Information
  • Founded
  • SYBX N/A
  • PT 2012
  • Country
  • SYBX United States
  • PT China
  • Employees
  • SYBX N/A
  • PT N/A
  • Industry
  • SYBX Biotechnology: Pharmaceutical Preparations
  • PT Computer Software: Programming Data Processing
  • Sector
  • SYBX Health Care
  • PT Technology
  • Exchange
  • SYBX Nasdaq
  • PT Nasdaq
  • Market Cap
  • SYBX 15.9M
  • PT 14.8M
  • IPO Year
  • SYBX N/A
  • PT 2018
  • Fundamental
  • Price
  • SYBX $1.43
  • PT $1.00
  • Analyst Decision
  • SYBX Buy
  • PT
  • Analyst Count
  • SYBX 4
  • PT 0
  • Target Price
  • SYBX $15.50
  • PT N/A
  • AVG Volume (30 Days)
  • SYBX 11.4K
  • PT 15.7K
  • Earning Date
  • SYBX 11-12-2024
  • PT 12-26-2024
  • Dividend Yield
  • SYBX N/A
  • PT N/A
  • EPS Growth
  • SYBX N/A
  • PT N/A
  • EPS
  • SYBX N/A
  • PT N/A
  • Revenue
  • SYBX $2,777,000.00
  • PT $4,479,352.00
  • Revenue This Year
  • SYBX N/A
  • PT N/A
  • Revenue Next Year
  • SYBX N/A
  • PT N/A
  • P/E Ratio
  • SYBX N/A
  • PT N/A
  • Revenue Growth
  • SYBX 292.23
  • PT N/A
  • 52 Week Low
  • SYBX $1.22
  • PT $0.71
  • 52 Week High
  • SYBX $5.12
  • PT $1.27
  • Technical
  • Relative Strength Index (RSI)
  • SYBX 50.79
  • PT 55.40
  • Support Level
  • SYBX $1.37
  • PT $0.95
  • Resistance Level
  • SYBX $1.45
  • PT $1.04
  • Average True Range (ATR)
  • SYBX 0.07
  • PT 0.06
  • MACD
  • SYBX 0.00
  • PT 0.01
  • Stochastic Oscillator
  • SYBX 31.82
  • PT 76.56

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees also by providing financing for these borrowers and earn installment service fees, They earn wealth management services fees and commission on financial products.

Share on Social Networks: